Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-355 PK, Safety and Tolerability Study
NCT03802162Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of donepezil and memantine in Alzheimer's disease (AD) (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration of D324, Area Under the Curve to Last Timepoint for D324 and 2 more. Started Feb 2019; status: completed.
02
Drugs
donepezilmemantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03802162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802162.